{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:01:54Z","timestamp":1788886914080,"version":"build-2803163510"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-CD38-based therapy has become a backbone regimen for the treatment of multiple myeloma (MM), approved in first-, second-, and third-line settings. The effectiveness of anti-CD38-based retreatment after an initial relapse on previous anti-CD38-based therapy is unclear. Here we present the results of a systematic literature review investigating the clinical outcomes of anti-CD38-based retreatment in patients with relapsed\/refractory MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medline\/Embase, congress publications, and other sources were searched (to December 8, 2023) for relevant articles in English and screened for eligibility criteria using the Population, Intervention, Comparator, Outcomes, Study Design (PICOS) framework, and data were then extracted for outcomes including progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2938 records were identified from the initial Medline\/Embase search and 11 were identified from other sources; 34 were eligible for inclusion, representing 24 studies (6 clinical [n=18\u2013307] and 18 real-world evidence [RWE; n=19\u2013583]). Where reported, median follow-up ranged from 1.9\u201343.0 months across 6 clinical and 8.7\u201353.0 months across 10 RWE studies. For clinical trials, anti-CD38-based retreatment resulted in a median PFS of 1.0\u20132.8 months in all but one trial (19.4 months), a median OS of 10.7\u201319.1 months (not reached in one trial), and ORRs of 0\u201375%. RWE studies reported a median PFS of 1.5\u20138.4 months, a median OS of 8.4\u201319.0 months (not reached in one study), and ORRs of 24.6\u201390.0%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Findings from this systematic literature review indicate that clinical outcomes with anti-CD38-based retreatment are variable and offer limited clinical benefit in patients with relapsed\/refractory MM, including in those refractory to anti-CD38-based treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1550644","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:20:37Z","timestamp":1741764037000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes associated with anti-CD38-based retreatment in relapsed\/refractory multiple myeloma: a systematic literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Francesca","family":"Gay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig Emmitt","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Chorazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ike","family":"Iheanacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Bitetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Boytsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Purser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","unstructured":"Cancer Stat Facts: Myeloma\n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050334","article-title":"Management of multiple myeloma: A review for general practitioners in oncology","volume":"30","author":"Monteith","year":"2023","journal-title":"Curr Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (Maia): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 benefit trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.1016\/S2152-2650(24)02264-X","article-title":"P-362 a real-world study to assess treatment patterns and outcomes of patients (Pts) with 2l+ Relapsed or refractory multiple myeloma in Italy, Germany, and the United Kingdom","volume":"24","author":"Gay","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B10","unstructured":"Darzalex\n          \n          2024"},{"key":"B11","unstructured":"Sarclisa\n          \n          2024"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","article-title":"Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: A US electronic health record database study","volume":"64","author":"Wang","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-cd38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17474086.2023.2154648","article-title":"Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States","volume":"16","author":"Varughese","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The prisma 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin Res Ed)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (Prisma-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ (Clin Res Ed)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clin Res Ed)"},{"key":"B19","unstructured":"2024"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12884","article-title":"Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the mixed methods appraisal tool (Mmat)","volume":"24","author":"Hong","year":"2018","journal-title":"J Eval Clin Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159424","article-title":"Retreatment of patients with anti cd38-based combinations in multiple myeloma in real-life: results from the emmy cohort study","volume":"140","author":"Hulin","year":"2022","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e90062ca","DOI":"10.1097\/01.HS9.0000967680.90062.ca","article-title":"Talquetamab (Tal) + Daratumumab (Dara) in patients (Pts) with relapsed\/refractory multiple myeloma (Rrmm): updated trimm-2 results","volume":"7","author":"Bahlis Nj","year":"2023","journal-title":"Hemasphere"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005220","article-title":"Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed\/refractory multiple myeloma","volume":"5","author":"Frerichs","year":"2021","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/cancers13102452","article-title":"Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients","volume":"13","author":"Frerichs","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5753","article-title":"Isatuximab in combination with cemiplimab in patients with relapsed\/refractory multiple myeloma: A phase 1\/2 study","volume":"12","author":"Lesokhin","year":"2023","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (Icaria-mm): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1182\/blood-2021-144387","article-title":"Efficacy of treatments for patients with triple-class refractory (Tcr) multiple myeloma (Mm): benchmark for new agents utilizing real-world data (Rwd)","volume":"138","author":"Costa","year":"2021","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162602","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma in real-life context in France: image subgroup analysis based on prior lines of therapy and refractory status","volume":"140","author":"Decaux","year":"2022","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165792","article-title":"Management and outcomes of anti-cd38 refractory myeloma patients: the impact of retreatment and of subsequent therapies","volume":"140","author":"Kastritis","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05218-1","article-title":"Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment","volume":"102","author":"Kikuchi","year":"2023","journal-title":"Ann Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000975260.78507.99","article-title":"Efficacy and immune modulation of daratumumab plus imid combination in patients refractory to both agents","volume":"7","author":"Kostopoulos","year":"2023","journal-title":"Hemasphere"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2021-154350","article-title":"Retrospective analysis of response rates to anti-cd38 monoclonal antibody containing regimens among multiple myeloma patients with prior exposure to daratumumab or isatuximab","volume":"138","author":"Yashar","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2949","article-title":"Salvage therapy with \u201cDara-kdt-P(a)Ce\u201d in heavily pretreated, high-risk, proliferative, relapsed\/refractory multiple myeloma","volume":"40","author":"Zhou","year":"2022","journal-title":"Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to cd38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13942","article-title":"Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma","volume":"110","author":"Abdallah","year":"2023","journal-title":"Eur J Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1186\/s12885-021-08881-7","article-title":"Treatment patterns and effectiveness of patients with multiple myeloma initiating daratumumab across different lines of therapy: A real-world chart review study","volume":"21","author":"Atrash","year":"2021","journal-title":"BMC Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158679","article-title":"Impact of daratumumab-containing regimens in outcomes of subsequent treatments of relapsed multiple myeloma in real-world practice from the Canadian myeloma research group database","volume":"140","author":"Leblanc","year":"2022","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010162","article-title":"Cd38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04555-3","article-title":"Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma patients-a single-center retrospective study","volume":"100","author":"Regidor","year":"2021","journal-title":"Ann Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160401","article-title":"Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on bcma-targeted car-T therapy","volume":"140","author":"Reyes","year":"2022","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26449","article-title":"The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy","volume":"97","author":"Szabo","year":"2022","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3209","article-title":"Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (\u201cPom-pad-dara\u201d) in relapsed\/refractory multiple myeloma","volume":"9","author":"Zhou","year":"2020","journal-title":"Cancer Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.492.492","article-title":"Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients","volume":"128","author":"Nooka","year":"2016","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7501","article-title":"Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (Ndmm ti)","volume":"42","author":"Leleu","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting gprc5d bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"New Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 monumental-1 results of talquetamab (Tal), a gprc5dxcd3 bispecific antibody (Bsab), for relapsed\/refractory multiple myeloma (Rrmm)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"key":"B49","unstructured":"Daratumumab Retreatment in Participants with Multiple Myeloma Who Have Been Previously Treated with Daratumumab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439","article-title":"Cd38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B51","unstructured":"A Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Participants with Multiple Myeloma\n          \n          2024"},{"key":"B52","unstructured":"A Study of Teclistamab in Combination with Daratumumab Subcutaneously (Sc) (Tec-Dara) Versus Daratumumab Sc, Pomalidomide, and Dexamethasone (Dpd) or Daratumumab Sc, Bortezomib, and Dexamethasone (Dvd) in Participants with Relapsed or Refractory Multiple Myeloma (Majestec-3)\n          \n          2024"},{"key":"B53","unstructured":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dvrd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dvrd) Followed by Autologous Stem Cell Transplant (Asct) in Participants with Newly Diagnosed Multiple Myeloma (Cartitude-6)\n          \n          2024"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II eloquent-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/cancers16061166","article-title":"Mezigdomide-a novel cereblon E3 ligase modulator under investigation in relapsed\/refractory multiple myeloma","volume":"16","author":"Hartley-Brown","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159710","article-title":"Isatuximab plus pomalidomide\/low-dose dexamethasone versus pomalidomide\/low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma (Icaria-mm): characterization of subsequent antimyeloma therapies","volume":"140","author":"Richardson","year":"2022","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/hs9.0000000000000566","article-title":"Updates from icaria-mm, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus pd in relapsed and refractory multiple myeloma (Rrmm)","volume":"5","author":"Perrot","year":"2021","journal-title":"Hemasphere"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8017","article-title":"Updates from icaria-mm, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus pd in relapsed and refractory multiple myeloma (Rrmm)","volume":"39","author":"Richardson","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"B60","unstructured":"A Study to Determine the Efficacy of the Combination of Daratumumab (Dara) Plus Durvalumab (Durva) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (Fusion-Mm-005)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2021-150032","article-title":"Evaluation of efficacy and immune modulation associated with the addition of imids to daratumumab backbone in patients refractory to both drug classes","volume":"138","author":"Fotiou","year":"2021","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2020-136323","article-title":"The addition of imids for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents","volume":"136","author":"Fotiou","year":"2020","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1097\/HS9.0000000000000975","article-title":"Management and outcomes of anti-cd38 refractory patients: the impact of retreatment and of subsequent therapies","volume":"7","author":"Kastritis","year":"2023","journal-title":"Hemasphere"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158270","article-title":"Real-world treatment patterns and outcomes of daratumumab retreatment in multiple myeloma in the United States","volume":"140","author":"Girvan","year":"2022","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1182\/blood-2021-152070","article-title":"The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy","volume":"138","author":"Szabo","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1550644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:20:41Z","timestamp":1741764041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1550644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":65,"alternative-id":["10.3389\/fonc.2025.1550644"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1550644","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1550644"}}